Greater frequency of PRAME-specific CD8+ T cells was evident in patients with AML, CML, and ALL than healthy controls, revealing the potential for developing PRAME as a target for immunotherapy in leukemia. Here, PRAME is linked to chronic myelogenous leukemia, BCR-ABL1 positive.